In the latest episode of The Line Podcast, recorded on October 30th, 2026, Matt Gurney and Jen Gerson begin with the newly released National Security Strategy. Your hosts agree that it's directionally correct, in that it's talking about the right things. But they also wonder whether this is going to be another example of a problem Prime Minister Mark Carney keeps discovering in government: it's one thing to say what should be done, and quite another to get the government bureaucracy to actually do it. Some of the problem is simply that the government hasn't had a clear sense of direction. A new strategy can help fix that. But a lot of it is going to come down to a bureaucracy that either cannot do what it's being told or will actively resist doing it. And the only way the PMO is going to fix that is by busting some heads. Metaphorically speaking, of course.

We hope.

This episode is brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-pro fit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: is Canada behind on immunotherapy?

Canadian researchers continue to be global leaders at discovery research. Where Canada lags behind is in bringing these discoveries from the lab to the patient. While many immunotherapies come to Canada for clinical trial or market authorization, few are based on Canadian research or developed in Canada, meaning we access them when their international sponsors choose, at whatever prices they want to charge –– provided Health Canada approves and the provinces decide to pay.

Developing more Canadian discoveries into approved therapies in Canada would help reduce Canada’s dependence on other countries, enable our health systems to learn what it takes to deliver these novel therapies while collecting data to assess their value via early stage clinical trials, and provide patients with much-needed access to advanced therapies. A win-win-win scenario.

BioCanRx continues to work with researchers and policymakers to deliver on this mission. Thanks to them for continuing to partner with The Line to share this information and visit BioCanRx.com to learn more.

Next, your hosts turn to a fascinating report by Christopher Nardi of the National Post, who took a deep dive into the challenges facing the Canadian Security Intelligence Service (CSIS). Matt and Jen praise the unusual transparency of CSIS director Dan Rogers, who agreed to be interviewed for the story. But Matt zeroes in on one particular thing Rogers told Nardi and throws up his hands in frustration. Because if Rogers actually means what he's saying, he's doomed. And CSIS with him. And the reasons are depressingly familiar to anyone who had already listened to ... the first segment of the podcast.

Finally, Matt and Jen discuss the ongoing negotiations between Canada and Europe. Hopefully nothing breaks later on the day of recording, but as things stand, your hosts are wondering why everyone has spent so much time arguing about what to call the relationship instead of explaining what the relationship will actually be. Speaking as two middle-aged people who would very much like to start spending their winters in southern Europe, they'd appreciate some actual progress on this front. And hopefully soon.

Oh, and, AI was asked to simulate a human civilization, and accidentally created Canada. It ended badly. So, yeah. There's that, too. Sigh.

All that and more in the latest episode of The Line Podcast.

#TheLinePodcast #MarkCarney #NationalSecurity #CanadianPolitics #CSIS #CanadianIntelligence #GovernmentBureaucracy #CanadaEuropeRelations #CanadianForeignPolicy #CurrentAffairs

In this episode of On The Line, BioCanRx President and CEO Stephanie Michaud joins Matt Gurney for a conversation about one of the biggest problems facing Canadian health care: Canada produces world-class medical research, but too often struggles to turn those discoveries into treatments that actually reach Canadian patients.

Stephanie explains why it can take so long for the newest and most promising therapies to make their way into the Canadian healthcare system — and why so much science developed by Canadian researchers ultimately ends up being commercialized in the United States. Canada has extraordinary researchers and institutions. So why do we keep losing the economic and medical benefits of their work?

This episode is brought to you by the Forest Products Association of Canada. Budget season in Ottawa is filled with asks for new programs, new tax measures and new investment. But for Canada’s forest products sector, the biggest opportunity for growth doesn’t require new spending — it requires smarter rules. Regulatory inefficiencies are costing the average Canadian mill an estimated one million dollars a year each. That’s money that could be reinvested in workers, communities, and modernization instead. The Forest Sector Transformation Task Force gave Ottawa a clear playbook. As the federal budget takes shape, the fastest way to unlock private investment is to remove the made-in-Canada barriers standing in the way. Learn more at FPAC.ca.

Matt and Stephanie also discuss what it would take for Canada to become more independent of the United States in biotechnology and healthcare. If Canadians really want to get their elbows up, this is one area where the country already has many of the ingredients it needs. They look at opportunities to work with international partners, build domestic capacity and create a system capable of taking Canadian discoveries from the laboratory all the way to Canadian patients.

And, unusually for On The Line, there’s some optimism. Stephanie believes Canada has a genuine opportunity to build on its existing strengths and become a global leader in biotechnology — creating economic opportunities while also helping Canadians survive terrible diseases and live longer, healthier lives.

This episode is also brought to you by Cameco. Building Canada’s energy future means creating jobs for Canadian workers. That’s why the AP1000 reactor is the right choice for Canada: it is already operating and ready to deliver the power we need. Choosing the AP1000 means a reactor built by Canadians, creating skilled jobs in construction, fabrication and the trades while keeping more investment and economic benefits here at home. If we are serious about creating Canadian jobs and strengthening our economy, the choice is clear. To learn more, visit ap1000.cameco.com.

Disclosures x 2: BioCanRx has been and remains a sponsor of The Line. This was an interview we wanted to do because of what Matt Gurney learned while his wife battled a devastating cancer diagnosis; an employee at BioCanRx is an old friend of Matt's and offered his help soon after the diagnosis, which is how The Line and BioCanRx began speaking in the first place. For the record: BioCanRx did not seek or receive any editorial control over this interview, was not provided questions in advance, nor asked for them, and requested no changes to the finished product. For further transparency, the only edits to this podcast were to cover your intrepid host choking while sipping water, like the seasoned broadcast professional he is, and a doorbell ringing. Exciting times!

Check out our main page at ReadTheLine.ca, and as always like and subscribe.

#OnTheLine #BioCanRx #StephanieMichaud #CanadianHealthcare #Biotechnology #CanadianInnovation #HealthInnovation #CancerResearch #LifeSciences #MedicalResearch #CanadaUS #MattGurney

In the latest episode of The Line Podcast, Matt Gurney returns from a leave to care for his wife and wonders if he’s missed anything over the last two weeks. Turns out he has. It’s his first chance to sit down with Jen Gerson and talk about the Alberta referendum, and Jen — finally having gotten some sleep — offers her concluding thoughts on … all that. Matt gives his reactions and asks Jen a fairly basic question: what, exactly, was the point of the whole exercise? They agree that Danielle Smith doesn’t come out of it looking particularly good. They also agree she might just skate anyway, especially since the separatists lost so badly that a lot of them might just move on to the next grift.

This episode is brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: is Canada behind on immunotherapy?

Canadian researchers continue to be global leaders at discovery research. Where Canada lags behind is in bringing these discoveries from the lab to the patient. While many immunotherapies come to Canada for clinical trial or market authorization, few are based on Canadian research or developed in Canada, meaning we access them when their international sponsors choose, at whatever prices they want to charge –– provided Health Canada approves and the provinces decide to pay.

Developing more Canadian discoveries into approved therapies in Canada would help reduce Canada’s dependence on other countries, enable our health systems to learn what it takes to deliver these novel therapies while collecting data to assess their value via early stage clinical trials, and provide patients with much-needed access to advanced therapies. A win-win-win scenario.

BioCanRx continues to work with researchers and policymakers to deliver on this mission. Thanks to them for continuing to partner with The Line to share this information and visit BioCanRx.com to learn more.

Next, your hosts turn to the catastrophe at CFB Wainwright, where some of the worst instincts of Canadian governance were on full display. The safety of the troops and care for the families of the fallen obviously come first. But the disaster also became a textbook example of how Canadian institutions respond to emergencies by smothering transparency. Matt and Jen go through what was known, what was revealed and, yes, read aloud what may be the worst official communication ever produced by a Canadian government comms person. Matt also responds to criticism that the military probably didn’t yet know the answers to the questions The Line wanted answered. There’s just one problem with that defence: someone leaked The Line the memo. They knew. So ....

Finally, Matt offers a personal update on the family medical emergency that took him away from the podcast. He’s still figuring out how much he can and should say publicly, but he has some broader thoughts about Canada’s health-care system. It turns out all the clichés are true: it can be astonishingly good and absolutely awful at the same time. Matt also has some very sharp and specific criticisms of one group of hospital professionals. He thinks the problems there are serious enough that they could end up collapsing the system, literally. Canadians will die because of this; Canadians are already dying of it, and Matt got to watch one of those deaths with his own eyes.

The harder question is what anyone can do about it.

All that, and more, in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe.

#TheLinePodcast

#AlbertaReferendum
#DanielleSmith
#CFBWainwright
#CanadianForces
#CanadianMilitary
#CanadianPolitics
#GovernmentTransparency
#CanadianHealthcare
#HealthcareCrisis